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Abstract
Background: Trials financed by for-profit organizations have been associated with favorable outcomes of new
treatments, although the effect size of funding source impact on outcome is unknown. The aim of this study was
to estimate the effect size for a favorable outcome in randomized controlled trials (RCTs), stratified by funding
source, that have been published in general medical journals.
Methods: Parallel-group RCTs published in The Lancet, New England Journal of Medicine, and JAMA between 2013
and 2015 were identified. RCTs with binary primary endpoints were included. The primary outcome was the OR of
patients’ having a favorable outcome in the intervention group compared with the control group. The OR of a favorable
outcome in each trial was calculated by the number of positive events that occurred in the intervention and control
groups. A meta-analytic technique with random effects model was used to calculate summary OR. Data were stratified
by funding source as for-profit, mixed, and nonprofit. Prespecified sensitivity, subgroup, and metaregression analyses
were performed.
Results: Five hundred nine trials were included. The OR for a favorable outcome in for-profit-funded RCTs was 1.92 (95%
CI 1.72–2.14), which was higher than mixed source-funded RCTs (OR 1.34, 95% CI 1.25–1.43) and nonprofit-funded RCTs
(OR 1.32, 95% CI 1.26–1.39). The OR for a favorable outcome was higher for both clinical and surrogate endpoints in
for-profit-funded trials than in RCTs with other funding sources. Excluding drug trials lowered the OR for a favorable
outcome in for-profit-funded RCTs. The OR for a favorable surrogate outcome in drug trials was higher in for-profit-
funded trials than in nonprofit-funded trials.
Conclusions: For-profit-funded RCTs have a higher OR for a favorable outcome than nonprofit- and mixed
source-funded RCTs. This difference is associated mainly with the use of surrogate endpoints in for-profit-
financed drug trials.
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Background
Results of well-conducted randomized controlled trials
(RCTs) are the most important building blocks of
evidence-based medicine and guide clinical manage-
ment. Clinical decisions based on RCTs rest on the
assumption that selection bias is reduced compared with
in nonrandomized trials. Randomization improves the
likelihood of balance between known and unknown
prognostic factors.
However, no study completely lacks confounding
factors and biases. Bias can be introduced into RCTs
during the entire study course. Imperfect study design,
lack of blinding, ascertainment bias, funding, publication
bias, and many more factors could all play an important
role in influencing the results of RCTs. If there are unre-
ported biases in RCTs influencing clinical guidelines,
these guidelines could potentially have been designed on
the basis of inadequate medical evidence and could
potentially hamper adequate clinical decision making.
Industry sponsorship has been shown to favor the com-
pany’s own product [1–3]. Earlier research on industry
funding and its impact on outcome in RCTs has been
focused on particular fields in medicine. Further, the
definition of a favorable outcome varies between different
studies or has been defined through the use of scoring
systems of trial conclusions [4–6] or on the basis of
reported outcomes [3], possibly in itself introducing bias.
The actual treatment effect associated with funding
source is unknown. Furthermore, the mechanisms
related to more favorable outcome in studies funded by
for-profit sources are conflicting. It has been suggested
by one group of authors to be caused by the use of
surrogate endpoints [7], but other authors have not been
able to confirm this [8].
To address the issue of the association of funding
source with outcome and follow-up regarding the imple-
mentation of the reporting of clinical trials, we evaluated
all parallel-group RCTs published in JAMA, The Lancet,
and New England Journal of Medicine between 2013 and
2015. The primary aim of this study was to calculate the
OR for a favorable outcome in the intervention group
compared with the control group in RCTs, stratified by




A librarian performed an electronic search to identify
studies published in JAMA, The Lancet, and New
England Journal of Medicine between 2013 and 23
September 2015. Trials were identified by using the
search terms “randomized controlled trials,” “N Eng J
Med,” “Lancet,” and “JAMA” in the PubMed database. A
full search strategy is presented in Additional file 1:
Table S1. The study followed the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.
Study selection
The following inclusion criteria were used:
1. Only two-armed RCTs were included.
2. RCTs with binary primary endpoints were included.
We decided a priori to study the primary outcome of
each study as stated in the published articles. When
primary outcome was a continuous variable and the
secondary outcome was binary (e.g., survival), the
secondary outcome was chosen for evaluation.
The following exclusion criteria were used:
1. Multiarm RCTs




The primary specified outcome was the OR of a favor-
able outcome in the intervention group compared with
the control group. The intervention group was defined
as the group receiving a new treatment compared with a
standard treatment or a control group. Favorable out-
come was defined as events that were favorable for the
patient (e.g., survival, progression free-survival, modified
Rankin Scale score 0–2). Unfavorable outcome was
defined as events that were unfavorable to the patient
(e.g., mortality, myocardial infarction, stroke, modified
Rankin Scale score 3–6). OR was calculated as the
number of events that occurred in the intervention and
control groups. Time-to-survival studies were included,
and the number of events that occurred during the study
period was used to calculate the OR. If the primary
endpoint was unfavorable (e.g., mortality), the number
of unfavorable events was subtracted from the total
number of patients in the respective treatment arm in
order to obtain the number of corresponding favorable
(in this case, survival) events to calculate the OR for a
favorable outcome.
A clinical endpoint was defined as events with a
direct consequence for the patient, such as mortality,
stroke, or improvement of symptoms. A surrogate
endpoint was defined as a measure with an indirect/
unclear consequence for the patient (e.g., biomarkers,
imaging, laboratory tests).
One author screened all search results and included
studies meeting all inclusion criteria. Outcome data were
extracted according to a prespecified protocol for each
study by one author. Outcome data were then hidden,
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and data on funding source were extracted. This proced-
ure was repeated twice. Data on funding were stratified
into three groups depending on funding type: for-profit
organization (as the only funding source), nonprofit
organization (as the only funding source), or mixed
funding with both for-profit and nonprofit funding (at
any percentage each). Free provision of drugs/devices to
studies was defined as funding and thus was assigned to
the for-profit-financed trial group if no nonprofit
organization participated in the study.
Statistical analysis
The Open Meta-Analyst (Center for Evidence Synthe-
sis in Health, Brown University, Providence, RI, USA
[9]) was used for all analyses. For each study, data
were analyzed to estimate the OR for a favorable
outcome by the published per-protocol analyses as
reported in the published article and according to the
intention-to-treat (ITT) population. In the ITT
analysis, a single imputation method was used, apply-
ing a worst-case scenario with unfavorable outcome
imputed for missing data. We obtained summary ORs
with corresponding 95% CIs for all outcome analyses.
An a priori use of the Mantel-Haenszel method with
a random effects model was applied. Outcome hetero-
geneity was evaluated with Cochrane’s Q test (signifi-
cance level cutoff value <0.10) and the I2 statistic
(significance cutoff value >50%). To also include zero
total events trials in the meta-analyses, an adjusted
continuity correction of 0.5 was applied [10]. To cal-
culate differences between ORs stratified for funding
source, a z-score was calculated by the logarithm (the
summary OR/SE to logarithmic OR), and a two-tailed
z-test was calculated to obtain a p value for the dif-
ference between ORs. To explore factors associated
with the magnitude of OR, we performed a metare-
gression where the dependent variable was OR for a
favorable outcome and the explanatory variables were
funding source, population size, intervention type,
journal, and type of endpoint (clinical/surrogate). A
logistic mixed effects model for the metaregression
implemented in R [11] as a plugin for Open Meta-A-
nalyst was used because it allows for both within-
study variation and between-study variation. To inves-
tigate differences in the OR between different sub-
groups, prespecified sensitivity analyzes were
performed, including medical fields, type of interven-
tion, type of endpoint, blinding, and comparator (pla-
cebo/nonplacebo) in drug trials. Because we had a
rather strict definition of funding source in which free
provision of drug was considered as sponsorship by
industry, we carried out a sensitivity analysis excluding
studies with industry-funded free provision of drugs.
Results
Description of included studies
The electronic search identified a total of 1149 publi-
cations, of which 509 RCTs fulfilled all inclusion
criteria. Topics covered all medical disciplines. One
hundred forty-eight (29%) trials were exclusively
funded by for-profit organizations, 117 (23%) trials
were jointly funded by for-profit and nonprofit
organizations, and 244 (48%) trials were exclusively
financed by nonprofit organizations.
Characteristics of the included studies are presented in
Table 1. There were no differences in study sample size
or the use of clinical and/or surrogate endpoints
between funding sources (Table 1).
Association of funding source on outcome
Calculation of the effect size for a favorable outcome in
the intervention group compared with the control group
was performed for all included studies and stratified for
funding source. The OR for a favorable outcome in for-
profit funded RCTs was 1.92 (95% CI 1.72–2.14), which
was higher than in the mixed-funded RCTs (OR 1.34,
95% CI 1.25–1.43). For-profit-funded RCTs had a higher
OR for a favorable clinical outcome than nonprofit-
funded RCTs (OR 1.32, 95% CI 1.26–1.39). No statistical
differences were found between the per-protocol and




nonprofit (n = 117)
Nonprofit
(n = 244)
Medical journal, n (%)
JAMA 17 (11%) 37 (32%)a 63 (26%)a
The Lancet 45 (30%) 33 (28%) 91 (37%)
New England Journal
of Medicine
86 (58%) 47 (40%)a 90 (37%)a
Sample size
Median 800 637 647
Intervention type, n (%)
Drug 118 (80%) 65 (56%)a 93 (38%)a,b
Device 18 (12%) 6 (5%) 16 (7%)
Procedure 4 (3%) 7 (6%) 42 (17%)a,b
Procedure and/or
device/drug/behavior
5 (3%) 21 (18%)a 21 (9%)b
Behavior 0 (0%) 1 (1%) 45 (18%)a,b
Other 3 (2%) 17 (15%)a 27 (11%)a
Endpoint, n (%)
Clinical 110 (74%) 91 (78%) 196 (80%)
Surrogate 38 (26%) 26 (22%) 48 (20%)
aDenotes statistical significant difference compared with the for-profit-funded
group (p < 0.05)
bDenotes statistical significant difference compared with mixed group funded
research (p < 0.05)
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ITT analyses (Table 2). There was considerable hetero-
geneity between the included studies (I2 73% to 96%).
Subgroup analyses, metaregression, and sensitivity
analyses
Medical field
Effect estimates in different medical fields and different
funding sources are presented in Table 3. For-profit-
funded RCTs had a higher OR for a favorable outcome
than nonprofit-funded RCTs for all medical fields except
diabetes, cardiovascular, and autoimmunity. The OR was
higher in for-profit-funded research than for mixed-
funded research in cardiovascular and autoimmunity
studies. Almost exclusively, behavioral intervention trials
were nonprofit-funded (n = 44). Excluding behavioral
intervention trials did not change the overall results for
the nonprofit group (OR 1.31, 95% CI 1.23–1.41). There
were no differences in the ORs between different
funding sources in device and procedure trials.
Metaregression
Metaregression was performed to assess the role of
moderator variables on the effect size. The following fac-
tors were included: sample size, medical journal, clinical/
surrogate endpoint, intervention type, and funding
source. The metaregression analysis showed that differ-
ences in OR could be explained by reporting on surro-
gate compared with clinical endpoints, as well as by
funding source, such as for-profit funding compared
with other funding sources. Furthermore, drug trials are
associated with a higher OR than device trials and
procedure trials in combination with other types of
intervention. Smaller sample size and medical journal
were not related to differences in effect size (Table 4).
Clinical and surrogate endpoints
The OR of a favorable outcome for clinical endpoints
was significantly higher in for-profit funded RCTs (OR
1.50, 95% CI 1.40–1.61) than in mixed-funded RCTs
(OR 1.27, 95% CI 1.16–1.34) and nonprofit-funded RCTs
(OR 1.27, 95% CI 1.19–1.37). This difference in OR
between for-profit and nonprofit/mixed-funded RCTs
was also seen in surrogate endpoints (Table 2).
When we stratified drug trials into clinical and surro-
gate endpoints, we found no difference in the OR of
clinical endpoints between funding sources. However,
we found significantly higher OR for surrogate end-
points in for-profit-funded drug trials (OR 4.10, 95%
CI 2.64–6.37) than in nonprofit-funded drug trials
(OR 1.66, 95% CI 1.11–2.47) (Table 5).
Drug trials
Excluding drug trials changed the OR from a statistical
difference depending on funding source to a nonsignifi-
cant difference in OR between funding. Placebo-
controlled for-profit drug trials had a higher OR than
mixed- and nonprofit-funded placebo drug trials.
Double-blind drug trials and non-double-blind trials had
a higher OR in for-profit-financed trials than nonprofit-
financed trials (Table 5). Non-placebo-controlled drug
trials with for-profit funding had a higher OR than
mixed-funded trials, but there was no difference from
nonprofit-funded research.
Discussion
In this study, we calculated the OR for a favorable
outcome in 509 RCTs published in general medical jour-
nals between 2013 and 2015, stratified by funding
source, and we investigated the underlying mechanisms
for differences in OR. RCTs funded by for-profit organi-
zations had a higher OR for a favorable outcome than
both nonprofit-funded and mixed-funded RCTs. The OR
for a favorable outcome was higher for both clinical and
surrogate endpoints in for-profit-funded trials than for
RCTs with other funding. The significant difference in
OR between for-profit- and nonprofit-funded RCTs was
lost when we excluded drug trials, indicating that a
higher OR is associated with drug trials. After stratifying
drug trials into clinical endpoints, we found no differ-
ences in OR between funding sources. For-profit-
financed drug trials in which researchers reported on
surrogate endpoints had a significantly higher OR of a
favorable outcome than nonprofit-financed drug trials.
We speculated that the resulting OR stratified for
funding source would differ between the per-protocol
and ITT analyses owing to differences in missing data
between studies. However, consistent with earlier
observations, our results contradicted this speculation,
showing no difference between the ITT and per-protocol
analyses [12].
The strengths of this study are the large number of
included studies (n = 509) from recent years. Trials from
Table 2 Meta-analysis comparing OR of favorable outcome, stratified by result analysis, primary outcome, and funding source
Funding source Per-protocol, OR (95% CI) Intention-to-treat, OR (95% CI) Clinical outcome, OR (95% CI) Surrogate outcome, OR (95% CI)
For-profit 1.92 (1.72–2.14) 1.74 (1.58–1.92) 1.50 (1.40–1.61) 3.72 (2.53–5.51)
Mixed 1.34 (1.25–1.43)a 1.30 (1.22–1.38)a 1.27 (1.16–1.34)a 1.57 (1.26–1.95)a
Nonprofit 1.32 (1.26–1.39)a 1.33 (1.26–1.40)a 1.27 (1.19,1.37)a 1.62 (1.46–1.76)a
aStatistical difference compared with for-profit-funded research (p < 0.05)
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all medical fields were included to fully study the
concept of funding influencing trial results. We analyzed
studies with binary outcomes, which are more com-
monly associated with hard clinical endpoints such as
progression-free survival than continuous variables,
which are more often surrogate markers such as blood
pressure [13]. In addition, we included studies with
time-to-survival rates and recorded the actual events at
a certain time point, because those studies are often con-
ducted in cancer fields and often financed by industry.
Using a meta-analytic technique, we were able to quantify
the effect size of a favorable outcome in the intervention
group compared with the control group on the basis of
actual study event rates of outcomes rather than scoring
systems. To our knowledge, the aggregated effect size
based on funding source has not been previously reported.
To limit bias in selecting reported outcomes we prespeci-
fied that we would study the primary study outcome as
reported in the published articles.
Limitations of this study are due mainly to the statis-
tical constraints of a meta-analysis combining different
study designs, populations, and interventions. A high
heterogeneity was expected in this study because differ-
ent studies with completely different outcomes from all
medical fields were included, along with a variety of
types of interventions. Also, the study design varied
between trials. Altogether, this yielded a high heterogen-
eity. However, in order to comprehensively explore the
size and magnitude of the association between funding
source and study outcome, a meta-analysis with appro-
priate sensitivity analyses was warranted.
There are several approaches to addressing heterogen-
eity [14]. We chose to explore heterogeneity by applying
metaregression analysis and a random effects model.
The metaregression analysis revealed that the use of
surrogate endpoints in clinical trials was associated with
higher OR than the use of clinical endpoints. Also, drug
trials were associated with a higher OR than device trials
or procedure trials in combination with other types of
interventions. Furthermore, the metaregression analysis
showed that for-profit-funded trials were associated with
higher OR than other funding sources. The inclusion of
small studies and medical journal type in the model did
not have a moderating variable effect on the meta-
analysis effect size (OR). These results contradict the
hypothesis that smaller studies are related to higher
treatment effects or that higher treatment effect is
associated with publication (e.g., New England Journal of
Medicine compared with The Lancet or JAMA). Given
the diversity of clinical conditions and outcomes that
were pooled in our analysis, we tried to adjust for differ-
ences in baseline characteristics by performing relevant
sensitivity analyses.
Our findings are in line with earlier studies demon-
strating an association between for-profit-funded re-
search and a more favorable outcome [1, 3, 5, 15];
however, these studies were based on data published
10–15 years ago. Previous research has been focused on
specific medical fields, such as cardiovascular research
[3], nutrition [16], or drug trials [5]. Our stratified
Table 3 Subgroup analysis of medical fields, stratified by funding source, comparing OR of favorable primary outcome between
intervention and control groups














Profit 1.89 (1.65–2.17) 1.83 (1.50–2.22) 1.96 (1.57–2.44) 2.12 (1.36–3.30) 4.34 (2.72–6.94) 1.86 (1.00–3.45) 2.52 (1.59–3.97)
Mixed funding 1.55 (1.26–1.90) 1.17 (1.03–1.20)a 1.45 (1.17–1.79) 1.57 (1.16–2.14) 1.46 (1.05–2.03)a 1.05 (0.91–1.20) 1.49 (0.96–2.07)
Nonprofit 1.13 (0.87–1.43)a 1.56 (1.37–1.76)b 1.33 (1.18–1.50)a 1.13 (0.97–1.32)a 2.39 (1.20–4.77) 1.12 (0.96–1.29) 1.31 (1.23–1.41)a
aDenotes statistical difference compared with the for-profit funded studies (p < 0.05)
bDenotes statistical difference compared with mixed funded studies (p < 0.05)
Table 4 Multivariate metaregression examining factors






JAMA −0.21 (−0.17, 0.12) 0.77
New England Journal of Medicine 0.024 (−0.10, 0.15) 0.70
Sample size
Mean 0 (0, 0) 0.76
Intervention type
Drug Reference
Device −0.21 (−0.40, −0.01) 0.04
Procedure 0.04 (−0.15, 0.23) 0.67
Procedure and/or device/drug −0.20 (−0.40, −0.00) 0.049
Behavior 0.02 (−0.19, 0.23) 0.85
Other −0.18 (−0.35, 0.00) 0.053
Endpoint
Clinical Reference
Surrogate 0.38 (0.25, 0.51) <0.001
Funding source
Profit Reference
Mixed −0.22 (−0.37, 0.07) 0.005
Nonprofit −0.28 (−0.42, −0.15) <0.001
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analysis for different medical fields showed a higher OR
for a favorable outcome in all groups except auto-
immunity, cardiovascular, and diabetes, with the highest
absolute OR being in autoimmunity trials. Our study
shows that the association between a higher OR for a
favorable outcome and for-profit-financed trials is con-
sistent in all medical fields. The OR for a favorable
outcome in for-profit-financed drug trials was higher in
placebo-controlled studies and double-blind studies than
in nonprofit-financed drug trials. Free provision of drugs
by industry is common in RCTs performed today, here
defined as mixed funding if the trial was otherwise
funded by a nonprofit organization. Excluding these
trials did not change the OR.
Previous studies of the association between funding
source and study outcome or conclusion have defined a
favorable outcome on the basis of either statistical
significance [16] or a scoring system [3, 5]. The ORs in
for-profit-funded research in these studies have not
been statistically different from nonprofit-funded
studies [5, 17, 18]. Two exceptions are trials investigating
nicotine replacement therapy [19] and glucosamine [20].
The authors of a Cochrane report published in 2012 stated
that the higher OR in industry-sponsored studies could be
mediated by unknown factors regarded as “metabias” [1].
There are several hypotheses explaining the differences
in rates of favorable outcome between studies. Differ-
ences due to variations in methodological quality are
unlikely in studies published in the included high-impact
journals, because study quality in general is higher in
high-impact journals than in other medical journals [21].
Probably, this is because many drug trials are almost
consistently conducted by contract research organiza-
tions, which are frequently multi-billion-dollar organiza-
tions that have more experience in conducting trials
than many academic centers and also have more risk
safeguards in place than many academic or nonprofit
centers. This has been further evaluated in a study by
Boutron et al. [22], who reported on the presence of
“spin” in RCTs with nonsignificant results for the
primary endpoint. In the study by Boutron et al., spin
was reported in studies published mainly in lower-
impact journals. Previous studies do not support the
notion that industry funding is associated with inferior
study quality [4, 23, 24]. Our results show that study
blinding and comparator group (e.g., active control or
placebo) poorly explain differences in effect size
between funding sources. Our findings suggest that
the use and selection of surrogate markers as primary
endpoints partly explain the difference in effect size
between funding sources.
One could argue that the differences in outcome be-
tween funding types can be explained by publication bias
whereby industry groups rarely publish negative results
and drug industry-funded research is less likely to be
published [15]. In accordance with these concepts, re-
search funded by drug companies has been reported to
be subject to selective publication, selective reporting,
and multiple publications [25]. Previous researchers
reported that pharmaceutical companies have sup-
pressed studies reporting severe adverse effects [26, 27].
Kasenda et al. [28] reported on reasons for discontinu-
ation of clinical trials. For-profit-funded studies were less
likely than nonprofit-funded trials to be discontinued
because of poor recruitment. Do pharmaceutical in-
dustries have a better availability of effective drugs?
This is partly contradicted by a study from Kasenda
et al., who found discontinuation of clinical trials
because of futility in equal proportions between for-
profit- and nonprofit-funded trials [28]. In analyzing
drug trials, they found that there were no differences
in effect sizes for clinical endpoints. This contradicts
the hypothesis that for-profit organizations have more
effective drugs. In addition, as reviewed by Svensson
et al., several drugs approved on the basis of surrogate
endpoints have later been shown to have substantial side
effects, impacting patients’ clinical course negatively [29].
In a RCT, Kesselheim et al. [30] compared how physi-
cians interpret trials depending on methodological dif-
ferences and funding sources. For-profit funding
reduced physicians’ willingness to believe the data. In
the last decade, several measures have been taken to
reduce selective reporting in trials through the introduc-
tion of trial registration [31] and the Consolidated
Standards of Reporting Trials (CONSORT) guidelines
[32]. The existence of industry-financed RCTs is
essential for the development of new drugs and modern
treatments. However, physicians’ mistrust of for-profit-
funded research is of great concern. Despite the latest
year’s implementation of trial registration and methodo-
logical guidelines for RCTs, the present study shows a
clear association between for-profit-financed studies and
a higher OR for a favorable outcome than for RCTs
supported by other types of funding.
The present study shows evidence that for-profit-
financed RCT researchers still report higher ORs,
despite recent years’ efforts to increase good research
conduct and transparency in RCTs. Recently, the Inter-
national Committee of Medical Journal Editors proposed
the concept of data sharing for clinical trials, enabling
secondary analyses of studies [33]. In a previous study,
Ebrahim et al. [34] evaluated reanalyses of published
RCTs and found that 35% of the reanalyses could alter
conclusions from those originally published, were the
original authors to have concluded that they were inept
in their analysis, further indicating this need for an open
access to published study data. Other strategies can con-
tain greater public funding of RCTs or “money-blind”
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independent organizations that would help to develop
trial methodology on the basis of industry funding. The
findings of the present study indicate that the use of
surrogate markers as primary endpoints should be
clearly stated as such in the abstracts of the trials, in
order not to overestimate the potential clinical benefit
for the individual patients.
Conclusions
Our study shows evidence supporting the hypothesis
that for-profit-financed RCTs are associated with a
higher OR for a favorable outcome of a new treat-
ment than nonprofit- and mixed-funded RCTs, and
that this difference is associated mainly with the use
of surrogate endpoints in for-profit-financed drug tri-
als. However, for-profit-financed drug trials with clin-
ical endpoints have ORs equal to those of trials with
other funding sources.
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